Abstract
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphoma......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
